# Verifying the Usefulness of Anticancer Drug-Degrading Agents Using the Residual Amount of Fluorouracil After Wiping as an Indicator

## TL;DR

This study tests two agents that reduce leftover fluorouracil, a chemotherapy drug, to improve safety for healthcare workers.

## Contribution

The study evaluates the effectiveness of two anticancer drug-degrading agents using fluorouracil residue as a measure.

## Key findings

- HD Protect and Tripleclin reduced fluorouracil residues more than the control method.
- The agents may be suitable for handling higher concentrations of fluorouracil.
- Wiping with these agents is confirmed as a useful method for reducing drug residues.

## Abstract

Long-term exposure to anticancer agents poses a health risk to healthcare workers and requires safety measures such as biological safety cabinets and personal protective equipment. The purpose of this study was to verify the usefulness of two anticancer drug-degrading agents, HD Protect (Secom Medical System Co. Ltd., Tokyo, Japan) and Tripleclin (Nipro Co. Ltd., Settsu, Japan), by analyzing residual amounts of fluorouracil (5-FU), which is frequently used in real clinical practice. Wiping with HD Protect and Tripleclin showed lower 5-FU residual concentrations than wiping with control in this study, indicating that they may be suitable for higher 5-FU concentrations. This study confirms the usefulness of wiping with anticancer drug-degrading agents to reduce 5-FU residues.